OPKO Health (OPK) to Present Short Bowel Syndrome Treatment in Prague

OPKO Health, Inc. (NASDAQ:OPK) is one of the penny stocks that will skyrocket. On July 8, the company confirmed that its oral GLP-2 tablet tailored for short bowel syndrome will be presented at the 47th European Society for Clinical Nutrition & Metabolism Congress in Prague.

The presentation is to be made on September 13, as part of an abstract titled “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome.” OPKO Health is developing an oral GLP-2 tablet in combination with Entera while leveraging its long-acting GLP-2 agonist.

“Given the heterogeneity of patients with SBS and challenging compliance rates attributed to injectable GLP-2 therapy, we believe a daily tablet format may enable more personalized care of this peptide and individualize titration,” said Miranda Toledano, Entera’s Chief Executive Officer.

The oral GLP-2 tablet targets the short bowel syndrome, a rare malabsorptive condition caused by significant loss of functional or physical bowel mass. The condition is characterized by the body’s failure to absorb nutrients and fluids, therefore putting patients at risk of malnutrition and unintended weight loss.

OPKO Health, Inc. (NASDAQ:OPK) is a diversified healthcare company that develops and commercializes pharmaceutical and diagnostic products. It creates solutions for serious diseases, including cancer and infectious diseases, leveraging pharmaceutical and diagnostic expertise.

While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 9 Best AI Stocks to Buy According to Billionaire Stanley Druckenmiller and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty.

Disclosure: None. This article is originally published at Insider Monkey.